Additional Listing

Lifeline Scientific, Inc.

("Lifeline" or the "Company")

Additional Listing

Lifeline Scientific (AIM: LSIC), the transplantation technology company, announces the issue of 11,929 unrestricted shares under ISIN number US53223V1017 following the cashless exercise of 50,000 share options.

Application has been made to the London Stock Exchange for admission to AIM of 11,929 common shares of USD0.01 each. It is expected that admission will become effective in the Shares on or around the 7 September 2015.

Subsequent to the admission above there will be 19,528,363 common shares in issue. Each share has the right to one vote. The Company holds no shares in Treasury. Therefore for the purposes of the FCA Disclosure and Transparency Rules the total number of voting rights in the Company is 19,528,363.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify the Company of their interests in, or change to their interests in, Lifeline Scientific, Inc. under the AIM Rules of the London Stock Exchange and the FCA's Disclosure and Transparency Rules.

For further information:

About Lifeline Scientific Inc.

Lifeline Scientific, Inc. is a Chicago-based global medical technology company with regional offices in Brussels and Sao Paulo. The Company's focus is the development of innovative products that improve transplant outcomes and lower the overall costs of transplantation. Its lead product, LifePort Kidney Transporter, is the global market-leading medical device for hypothermic machine preservation of donor kidneys. LifePorts and novel solutions designed for preservation of other organs are in development, with LifePort Liver Transporter next in line for commercial launch. For more information please visit www.lifeline-scientific.com

About LifePort Kidney Transporter

Created with the challenges of organ recovery and transport in mind, LifePort Kidney Transporter is a proprietary medical device designed to help improve kidney preservation, evaluation and transport prior to transplantation. It has been widely studied in clinical trials throughout the world and is the standard of care for machine preservation of kidneys. Employed by surgeons in over 200 leading transplant programmes in 28 countries, LifePorts have successfully preserved more than 50,000 kidneys indicated for clinical transplant. For more information please visit www.organ-recovery.com

About LifePort Liver Transporter

LifePort Liver Transporter is modelled upon the clinically proven technology platform of LifePort Kidney Transporter and the Company's early HMP prototype successfully used in clinical transplant studies by surgeons at New York-Presbyterian Hospital/Columbia University Medical Center. LifePort Liver Transporter and the Company's proprietary machine preservation solution, Vasosol®, are in the process of US and international regulatory registrations. The system is designed to help improve outcomes in liver transplantation by enabling the clinical use of hypothermic machine perfusion, and has been developed in consultation with clinical and research teams specialising in liver transplantation at Columbia University Medical Center and the University of Chicago. The system employs a rugged, streamlined ergonomic design for ease of use and transportability from donor bedside to recipient operating room. For more information please visit: http://www.organ-recovery.com/pipeline.php